Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Correspondence to: Elizabeth B. Lamont, MD, MS, Massachusetts General Hospital Cancer Center, 55 Fruit St., Suite: Zero Emerson Place, Boston, MA 02114 (e-mail: elamont{at}partners.org’ + u + ‘@’ + d + ”//–>) We appreciate Drs. Muñoz and Samet’s careful review of our manuscript and the opportunity to provide additional details and results from our work. They have one main methodologic concern and several related empiric statistical questions regarding our study. Their overarching methodologic concern is that multivariable regression may not be able to adjust appropriately for the extreme differences in prognostically important covariates (e.g., race, income, tumor site, extent of disease) between the two groups of patients (i.e., those patients living 15 miles from the center and those living >15 miles from the center). With respect to empirical questions, Drs. Muñoz and Samet ask for a number of statistical details to evaluate the possibility that the association we found between tr
